



Breast cancer is the most frequently diagnosed cancer among women, impacting 2.1 million women worldwide each year and causing the greatest number of cancer-related deaths amongst women. It is estimated that 627,000 women died from breast cancer in 2018, approximately 15% of all cancer-related female deaths. Whilst breast cancer rates are higher among women in more developed regions, rates are increasing in nearly every region globally.

Breast Cancer Statistics

Screening mammography is the mechanism used globally for early detection of breast cancer and it is well-established that breast cancer screening programs reduce mortality by at least 20%.

A classic mammogram consists of four x-ray images, two for each breast.

In most of the world it is routinely performed on women aged 40-75 every two years. The screening window can be as narrow as 50-69 years old and be performed on a yearly basis (some places in the US) or every three years (in the UK).

Due to the vast number of performed mammography studies (40M annually in the US alone) and insufficient number of trained radiologists, there is a lack of manpower to handle the increasing workloads.

MAMMO SOLUTION

An automatic AI tool that indicates 'suspicious' or 'not suspicious' for every 2D mammography performed (that matches the criteria, e.g. no previous cancer, no implants etc.)

Zebra-Med's mammo solution is FDA cleared and CE marked.




HOW IT WORKS

The PACS forwards imaging scans to the Zebra-Med Analytics engine. Once the Zebra-Med Engine receives the images, the algorithm runs on the scans and provides all available insights. Upon completion, the images are deleted and the algorithm results are stored and are accessible to the radiologist in his/her workstation.

The installation of this product is done via integration with the PACS. Once installed, new solutions can be added seamlessly without the need for additional technical efforts.

The Zebra-Med engine analytics can be installed on-premise or via AWS cloud.



THE PROVIDERS WE HELP

A screening mammography clinic, with a high workload of screening mammograms (usually 100-300 per day).

MAIN VALUE

The triage product acts as a pre-reading of the screening studies, allowing the radiologists to address the suspicious ones first; alternatively, the cases could be divided between experienced and inexperienced radiologists.

An additional use case is to provide a result after being read by the radiologists, thereby acting as a second reader and a safety-net

for the screening program.





